Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023Bojana Milojkovic Kerklaan, Bojana Milojkovic Kerklaan, Veronique Diéras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
European Journal of Radiology|September 25, 2010
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patientsIngrid M E Desar, Carla M L van Herpen, Jack J A van Asten, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
The European Respiratory Journal|June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA"Patrick Schöffski, Maud Toulmonde, Anna Estival, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'Patrick Schöffski, Olivier Mir, Bernd Kasper, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2012
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012Matthias Preusser, Frank Winkler, Laurence Collette, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
Pageof 7